USA - NASDAQ:NOTV - US45783Q1004 - Common Stock
The current stock price of NOTV is 1.4 USD. In the past month the price increased by 1.45%. In the past year, price decreased by -18.13%.
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| TMO | THERMO FISHER SCIENTIFIC INC | 25.56 | 216.18B | ||
| DHR | DANAHER CORP | 28.92 | 159.69B | ||
| BRKRP | BRUKER CORP - BRKR 6 3/8 09/01/28 | 148.65 | 48.49B | ||
| A | AGILENT TECHNOLOGIES INC | 27.16 | 41.97B | ||
| IQV | IQVIA HOLDINGS INC | 19.23 | 37.49B | ||
| MTD | METTLER-TOLEDO INTERNATIONAL | 35.07 | 29.55B | ||
| WAT | WATERS CORP | 29.39 | 21.40B | ||
| WST | WEST PHARMACEUTICAL SERVICES | 42.07 | 21.39B | ||
| MEDP | MEDPACE HOLDINGS INC | 42.32 | 17.00B | ||
| TEM | TEMPUS AI INC | N/A | 15.50B | ||
| ILMN | ILLUMINA INC | 24.06 | 15.39B | ||
| ICLR | ICON PLC | 13.5 | 13.85B |
Inotiv, Inc. is a pharmaceutical development company, which engages in the provision of nonclinical and analytical drug discovery and development services primarily to the pharmaceutical and medical device industries and selling a range of research-quality animals and diets to academia and government clients. The company is headquartered in West Lafayette, Indiana and currently employs 1,977 full-time employees. Its products and services focus on bringing new drugs and medical devices through the discovery and preclinical phases of development. The company operates through two segments: Discovery and Safety Assessment (DSA) and Research Models and Services (RMS). Through DSA segment, it supports the discovery, nonclinical development and clinical development needs of researchers and clinicians for primarily small molecule drug candidates, as well as biotherapeutics and biomedical devices. Through RMS segment, it offers access to a range of small and large research models for basic research and drug discovery and development, as well as specialized models for specific diseases and therapeutic areas.
INOTIV INC
2701 Kent Ave
West Lafayette INDIANA 47906 US
CEO: Robert W. Leasure Jr.
Employees: 2026
Phone: 13174634527
Inotiv, Inc. is a pharmaceutical development company, which engages in the provision of nonclinical and analytical drug discovery and development services primarily to the pharmaceutical and medical device industries and selling a range of research-quality animals and diets to academia and government clients. The company is headquartered in West Lafayette, Indiana and currently employs 1,977 full-time employees. Its products and services focus on bringing new drugs and medical devices through the discovery and preclinical phases of development. The company operates through two segments: Discovery and Safety Assessment (DSA) and Research Models and Services (RMS). Through DSA segment, it supports the discovery, nonclinical development and clinical development needs of researchers and clinicians for primarily small molecule drug candidates, as well as biotherapeutics and biomedical devices. Through RMS segment, it offers access to a range of small and large research models for basic research and drug discovery and development, as well as specialized models for specific diseases and therapeutic areas.
The current stock price of NOTV is 1.4 USD. The price increased by 3.7% in the last trading session.
NOTV does not pay a dividend.
NOTV has a ChartMill Technical rating of 1 out of 10 and a ChartMill Fundamental rating of 2 out of 10.
This depends on your investment goals. Check the Technical and Fundamental Analysis tabs for insights on NOTV.
INOTIV INC (NOTV) has a market capitalization of 48.09M USD. This makes NOTV a Nano Cap stock.
You can find the ownership structure of INOTIV INC (NOTV) on the Ownership tab.
ChartMill assigns a technical rating of 1 / 10 to NOTV. When comparing the yearly performance of all stocks, NOTV is a bad performer in the overall market: 91.17% of all stocks are doing better.
ChartMill assigns a fundamental rating of 2 / 10 to NOTV. Both the profitability and financial health of NOTV have multiple concerns.
Over the last trailing twelve months NOTV reported a non-GAAP Earnings per Share(EPS) of -2.7. The EPS increased by 29.69% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -10.39% | ||
| ROE | -54.92% | ||
| Debt/Equity | 2.73 |
9 analysts have analysed NOTV and the average price target is 5.61 USD. This implies a price increase of 300.71% is expected in the next year compared to the current price of 1.4.
For the next year, analysts expect an EPS growth of 43.04% and a revenue growth 6.5% for NOTV